GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Talecris Biotherapeutics (TLCR) [hlAlert]

Rating:
Outperform
TLCR
up 31.02 %

Talecris Biotherapeutics (TLCR) rated Outperform by Wells Fargo

Posted on: Tuesday,  Nov 10, 2009  8:25 AM ET by Wells Fargo

Wells Fargo rated Outperform Talecris Biotherapeutics (TLCR) on 11/10/2009, when the stock price was $21.98. Since then,
Talecris Biotherapeutics has gained 31.03% as of 05/31/2011's recent price of $28.80.
If you would have followed this Wells Fargo's recommendation on TLCR, you would have gained 31.02% of your investment in 567 days.

Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that is a producer and marketer of plasma-derived protein therapies in the world. The Company develops, produces, markets and distributes therapies that help people suffering from conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns. The Company?s largest product, Gamunex Immune Globulin Intravenous (Human), is one of the products in the intravenous immune globulin (IGIV) market. Its second largest product, Prolastin Alpha 1 Proteinase Inhibitor (Human), was granted orphan drug status and has a 71% share of sales in the United States, a 78% share of sales in the European Union and brand recognition within the alpha-1 proteinase inhibitor (A1PI) category. In June 2007, it acquired three additional plasma collection centers from International BioResources, L.L.C. (IBR).

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/10/2009 8:25 AM Buy
None
21.98
as of 12/31/2009
1 Week up  4.32 %
1 Month up  27.36 %
3 Months up  7.22 %
1 YTD up  7.22 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy